Citations

Clear

4207 citation(s) found for "Chen, Yu".

Absence of the intracellular lipolytic inhibitor G0S2 enhances intravascular triglyceride clearance and abolishes diet-induced hypertriglyceridemia
Chen, Yongbin , Johnson, Scott , Burr, Stephanie D. , Povero, Davide , Anderson, Aaron , McMahon, Cailin E., Liu, Jun , Johnson, S. M. , Liu, Jun , Johnson, Scott M., Liu, Jun

Mayo Clinic

Journal of Clinical Investigation | March 18, 2025 | Volume: 135 | Issue: 10 | Pages: No page available

10.1172/jci181754 | PMID 40100923 Get It

The interplay between intracellular and intravascular lipolysis is crucial for maintaining circulating lipid levels and systemic energy homeostasis. Adipose triglyceride lipase (ATGL) and lipoprotein lipase (LPL), the primary triglyceride (TG) lipases responsible for these two spatially separate processes, are highly expressed in adipose tissue. Yet the mechanisms underlying their coordinated regulation remain undetermined. Here, we demonstrate that genetic ablation of G0S2, a specific inhibitory protein of ATGL, completely abolished diet-induced hypertriglyceridemia and significantly attenuated atherogenesis in mice. These effects were attributable to enhanced whole-body TG clearance, not altered hepatic TG secretion. Specifically, G0S2 deletion increased circulating LPL concentration and activity, predominantly through LPL production from white adipose tissue (WAT). Strikingly, transplantation of G0S2-deficient WAT normalized plasma TG levels in mice with hypertriglyceridemia. In conjunction with improved insulin sensitivity and decreased ANGPTL4 expression, the absence of G0S2 enhanced the stability of LPL protein in adipocytes, a phenomenon that could be reversed upon ATGL inhibition. Collectively, these findings highlight the pivotal role of adipocyte G0S2 in regulating both intracellular and intravascular lipolysis, and the possibility of targeting G0S2 as a viable pharmacological approach to reducing levels of circulating TGs.
RBAD: A Dataset and Benchmark for Retinal Vessels Branching Angle Detection
Zhu, Wenhui , Qin, Jiayou, Li, Xin , Dumitrașcu, Oana , Chen, Xiwen , Razi, Abolfazl , Wang, Hao Henry , Qiu, Peijie , Wang, Yalin

Mayo Clinic

2024 IEEE EMBS International Conference on Biomedical and Health Informatics (BHI) | March 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.1109/bhi62660.2024.10913865 | PMID 40356674 Get It

Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
Yin, Jinhu , Leduc, Charles , Sholl, Lynette M. , McElderry, John, Hartman, Caleb , Rosenbaum, Jennifer, Colón-Matos, Frank J. , Miraftab, Mona , Caporaso, Neil E. , Wong, Maria Pik , Leung, Kin Chung, Hsiung, Chao A. , Chen, Chih-Yi, Edell, Eric S. , Santamaría, Jacobo Martínez, Mańczuk, Marta , Mukeria, Anush, Shangina, Oxana , Заридзе, Давид , Mates, Dana, Milosavljević, Saša , Savić, Milan , Gaborieau, Valérie , Hofman, Paul L. , Yang, Lixing , Shi, Jianxin , Brown, Kevin M. , Rothman, Nathaniel , Choi, Jiyeon , Lan, Qing , Wedge, David C. , Landi, Maria Teresa , Chen, Chih‐Yi , Manczuk, Marta , Chen, Chih-Yi , Leduc, Charles , Zhang, Tongwu , Zhao, Wei , Wirth, Christopher, Díaz‐Gay, Marcos , Cecati, Monia , Marchegiani, Francesca , Hoang, Phuc H. , Baine, Marina K , Travis, William D. , Joubert, Philippe , Sang, Jian , Klein, Alyssa , Khandekar, Azhar , Saha, Monjoy , Lee, Olivia W. , Jones, Kristine , Santamaría, Jacobo Martínez, Schabath, Matthew B. , Yendamuri, Sai S , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Milosavljevic, Sasa , Bossé, Yohan , Gould Rothberg, Bonnie E , Christiani, David C. , Brennan, Paul Martin , Liu, Geoffrey , Hofman, Paul , Homer, Robert , Yang, Soo-Ryum , Pesatori, Angela C , Consonni, Dario , Zhu, Bin , Chanock, Stephen Jacob , Alexandrov, Ludmil B. , Cardelli, Maurizio , Nowak, Martin A.

Mayo Clinic

No container title available | March 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643063 | PMID 40161734 Get It

ABSTRACT Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUAD that displayed diverse clonal architecture. In this group, we observed an interplay between mobile elements, endogenous and exogenous mutational processes, distinct driver genes, and epidemiological features. Our results revealed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry, and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS plus short subclonal diversification. LUAD in never smokers showed early occurrence of copy number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumors harboring EGFR mutations exhibited long latency, particularly in females of European-ancestry (EU_N). In EU_N, EGFR mutations preceded the occurrence of other driver genes, including TP53 and RBM10. Tumors from Asian never smokers showed a short clonal evolution and presented with heterogeneous repetitive patterns for the inferred mutational order. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumors with ID2 showed short latency and high L1 retrotransposon activity linked to L1 promoter demethylation. These tumors exhibited an aggressive phenotype, characterized by increased genomic instability, elevated hypoxia scores, low burden of neoantigens, propensity to develop metastasis, and poor overall survival. Re-activated L1 retrotransposition-induced mutagenesis can contribute to the origin of the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695 , a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, Meera , Hung, Kevin , Baranwal, Anmol , Al‐Kali, Aref , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Shah, Syed Naseem, Khanna, Shreyas, Ladon, Dariusz, Gannamani, Vedavyas, Begna, Kebede H. , Price, Zoe, Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Badar, Talha , Kumar, Sharad , Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Scott, Hamish S. , Mangaonkar, Abhishek A. , Hahn, Christopher N , Tefferi, Ayalew , Hiwase, Devendra , Shah, Mithun V , Kutyna, Monika M , Al-Kali, Aref , Toop, Carla , Greipp, Patricia T , Brown, Anna L , Begna, Kebede , Litzow, Mark R. , Hogan, William J , Badar, Talha , Kumar, Sharad , Patnaik, Mrinal , He, Rong , Gangat, Naseema , Scott, Hamish , Arana Yi, Cecilia , Hahn, Christopher , Arber, Daniel A , Kok, Chung H , Hiwase, Devendra , Baranwal, Anmol , Hung, Kevin , Kutyna, Monika , Chen, Dong , Price, Zoe K. , Hogan, William J. , Yeung, David , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow

Mayo Clinic

Blood Advances | March 14, 2025 | Volume: 9 | Issue: 13 | Pages: 3370-3380

10.1182/bloodadvances.2024015238 | PMID 40085954 Get It

Abstract This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF <10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with <5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF <10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.
Clinical neurocardiology: defining the value of neuroscience‐based cardiovascular therapeutics – 2024 update
Aksu, Tolga , Arora, Rishi , Chen, Peng‐Sheng , Fudim, Marat , Herring, Neil , Po, Sunny S. , Stavrakis, Stavros , Somers, Virend K. , Tan, Alex Y. , Valderrábano, Miguel , Shivkumar, Kalyanam , Shivkumar, Kalyanam , Ajijola, Olujimi A. , Biaggioni, Italo , Ferrari, Gaetano Maria De , Dusi, Veronica , Goldberger, Jeffrey J , Green, Alexander L. , Khalsa, Sahib S. , Kumar, Rajesh , Lakatta, Edward G. , Mehra, Reena , Meyer, Christian , Somers, Virend K.

Mayo Clinic

The Journal of Physiology | March 12, 2025 | Volume: 603 | Issue: 7 | Pages: 1781-1839

10.1113/jp284741 | PMID 40056025 Get It

AbstractThe intricate role of the autonomic nervous system (ANS) in regulating cardiac physiology has long been recognized. Aberrant function of the ANS is central to the pathophysiology of cardiovascular diseases. It stands to reason, therefore, that neuroscience‐based cardiovascular therapeutics hold great promise in the treatment of cardiovascular diseases in humans. A decade after the inaugural edition, this White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology and pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases. image
Automated Von Willebrand Factor Multimer Image Analysis for Improved Diagnosis and Classification of Von Willebrand Disease
Ks, Anand, Olteanu, V.A., Zhang, Chi , Nelton, Katelynn J., Aakre, Erin, Pruthi, Rajiv K. , Chen, Dong , Seheult, Jansen N. , Nelton, Katelynn, Botero, Juliana Perez , Pruthi, Rajiv K , Chen, Dong , Seheult, Jansen N , Anand, Karthik

Mayo Clinic

International Journal of Laboratory Hematology | March 12, 2025 | Volume: 47 | Issue: 4 | Pages: 730-737

10.1111/ijlh.14455 | PMID 40025642 Get It

ABSTRACTIntroductionVon Willebrand factor (VWF) multimer analysis is essential for diagnosing and classifying von Willebrand disease (VWD) but requires expert interpretation and is subject to inter‐rater variability. We developed an automated image analysis pipeline using deep learning to improve the reproducibility and efficiency of VWF multimer pattern classification.MethodsWe trained a YOLOv8 deep learning model on 514 gel images (6168 labeled instances) to classify VWF multimer patterns into 12 classes. The model was validated on 192 images (2304 instances) and tested on an independent set of 94 images (1128 instances). Images underwent preprocessing, including histogram equalization, contrast enhancement, and gamma correction. Two expert raters provided ground truth classifications.ResultsThe model achieved 91% accuracy compared to Expert 1 (macro‐averaged precision = 0.851, recall = 0.757, F1‐score = 0.786) and 87% accuracy compared to Expert 2 (macro‐averaged precision = 0.653, recall = 0.653, F1‐score = 0.641). Inter‐rater agreement was very high between experts (κ = 0.883), with strong agreement between the model and Expert 1 (κ = 0.845) and good agreement with Expert 2 (κ = 0.773). The model performed exceptionally well on common patterns (F1 > 0.93) but showed lower performance on rare subtypes.ConclusionAutomated VWF multimer analysis using deep learning demonstrates high accuracy in pattern classification and could standardize the interpretation of VWF multimer patterns. While not replacing expert analysis, this approach could improve the efficiency of expert human review, potentially streamlining laboratory workflow and expanding access to VWF multimer testing.
Abstract A011: ATM inhibitors exploit checkpoint defects and ATM-dependent double strand break repair to induce mitotic cell death in TP53-mutant glioblastoma
Chen, Jiajia , Carlson, Brett L. , Calmo, Nery Matias , Tian, Shulan , Laverty, Daniel J. , Gupta, Shiv K. , Bradshaw, Gary Andrew , Sarkaria, Jann N. , Nagel, Zachary D

Mayo Clinic

Cancer Research | March 11, 2025 | Volume: 85 | Issue: 5_Supplement | Pages: A011-A011

10.1158/1538-7445.genfunc25-a011 Get It

Abstract Determining the balance between DNA double strand break repair (DSBR) pathways is essential for understanding treatment response in cancer. We report a method for simultaneously measuring non-homologous end joining (NHEJ), homologous recombination (HR), and microhomology-mediated end joining (MMEJ) and show that HR and MMEJ are therapeutically-targetable treatment resistance mechanisms in glioblastoma. Using a targeted screen of clinically relevant small molecules, we identify the ATM kinase inhibitor, AZD1390, as a potent dual HR/MMEJ inhibitor. Mechanistic studies in GBM cell lines show that AZD1390 suppresses DSB end resection and blocks radiation-induced phosphorylation of DSBR proteins including nibrin, Rad50, and Mettl16. Interestingly, AZD1390 enhances the cytotoxic effects of TMZ and radiation in both treatment-naïve and treatment-resistant GBM samples harboring mutations in the TP53 gene. We show that TP53 mutation is associated with upregulation of ATM pathway genes in GBM patient samples along with heightened ATM-dependent HR and MMEJ in GBM cell lines. Finally, we show that TP53-mutant GBMs fail to arrest in G2 phase after radiation/AZD1390 or TMZ/AZD1390 combinations and instead attempt mitosis, leading to mitotic cell death. Expression of the mitotic DSBR factor, RHINO1, is associated with poor prognosis in patients with TP53-mutant GBMs, suggesting that factors that promote efficient mitotic DSBR protect TP53-mutant GBMs from treatment-induced cell death. This report identifies ATM-dependent HR and MMEJ as targetable resistance mechanisms in TP53-mutant GBM and establishes ATM inhibition as a potential strategy for overcoming intrinsic and acquired treatment resistance in TP53-mutant GBMs. Citation Format: Daniel J Laverty, Shiv Gupta, Gary Bradshaw, Jiajia Chen, Brett L Carlson, Nery Matias Calmo, Shulan Tian, Jann N Sarkaria, Zachary D Nagel. ATM inhibitors exploit checkpoint defects and ATM-dependent double strand break repair to induce mitotic cell death in TP53-mutant glioblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals; 2025 Mar 11-13; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(5 Suppl):Abstract nr A011.
Free‐breathing hepatic 2D magnetic resonance elastography
Li, Jiahui , Chen, Jie , Glaser, Kevin J. , Yin, Ziying , Le, Yuan , Shah, Vijay H. , Obrzut, Marzanna, Yin, Ziying , Le, Yuan , Manduca, A , Ehman, Richard , Li, Jiahui , Obrzut, Marzanna , Dzyubak, Bogdan , Chen, Jun , Allen, Alina M. , Venkatesh, Sudhakar K. , Manduca, Armando , Ehman, Richard L. , Yin, Meng

Mayo Clinic

Magnetic Resonance in Medicine | March 11, 2025 | Volume: 93 | Issue: 6 | Pages: 2434-2443

10.1002/mrm.30483 | PMID 40033890 Get It

Abstract Purpose To evaluate the test–retest repeatability of a rapid, free‐breathing two‐dimensional (2D) MR elastography (MRE) technique and to assess the reliability of the liver‐stiffness measurements compared with conventional breath‐hold MREs. Methods Fifteen and 115 participants were enrolled in the technical repeatability and measurement equivalence assessment cohorts, respectively. All participants underwent rapid free‐breathing and conventional breath‐hold 2D MRE (twice in repeatability cohort) on 1.5T scanners. Both methods have four phase offsets over one harmonic motion cycle at 60 Hz; one and 10 cycles were collected and processed in breath‐hold and free‐breathing MREs, respectively. The liver stiffness measurements of free‐breathing (LS F ) and breath‐hold MRE (LS B ) were calculated from manually drawn regions of interest. The repeatability coefficients and Spearman correlation were used to assess technical repeatability and measurement agreement between LS F and LS B . Univariable and multivariable linear regressions were performed to identify potential influencing factors, including age, sex, body mass index, and fat fraction, in the measurement agreement between LS B and LS F . Results The repeatability coefficient of free‐breathing 2D MRE is comparable to breath‐hold MRE (LS F : 20.8%, LS B : 20.4%). LS F showed a strong agreement and significant correlation with LS B (LS F = 1.01 × LS B , ρ = 0.94, p < 0.001). The measurement agreement between LS F and LS B was only significantly affected by sex ( p = 0.047) after adjusting for confounding factors of age, body mass index, and fat fraction. Conclusions The nongated, free‐breathing, multislice 2D MRE technique can provide reliable liver stiffness measurements compared with conventional breath‐hold 2D MRE. It could provide a comfortable alternative method with reliable liver stiffness measurements for patients who have difficulty in suspending respiration.
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer
Chen, Li , Mansfield, Aaron S. , Lheureux, Stéphanie , O’Connor, C.J., Zamboni, Beth A., Patel, Kashish, McKee, Tawnya C., Moscow, Jeffrey A. , Zamboni, William C. , Mansfield, Aaron S , Lheureux, Stephanie , Moscow, Jeffrey A , Lucas, Andrew T.

Mayo Clinic

Clinical and Translational Science | March 11, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/cts.70178 | PMID 40051118 Get It

ABSTRACTAnetumab ravtansine, like other ADC drugs, has high inter‐patient variability in its pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, which raises concerns about whether current dosing regimens are optimal for patients. The objective of this study was to evaluate covariates, especially body habitus and the innate immune system (IIS), which may affect anetumab ravtansine PK and PD as part of two clinical trials in patients with ovarian cancer and mesothelioma. Biomarkers of Fcγ receptors(FcγR) CD64 on IIS cells, total body weight (TBW), body surface area (BSA), and other covariates, such as sex and age, were analyzed for an association with anetumab ravtansine PK. Higher FcγR CD64, TBW, and BSA were associated with higher clearance (CL) of anetumab ravtansine (p < 0.05). However, there was no relationship between TBW or BSA and FcγR CD64. Female patients had a lower anetumab ravtansine CL (0.030 ± 0.007 L/h) compared to male patients (0.042 ± 0.006 L/h) (p < 0.05). In both studies, patients with stable disease (SD) and partial response (PR) had higher anetumab ravtansine AUC0‐inf compared to patients with progressive disease (PD). Individualizing the dose of anetumab ravtansine and potentially other ADCs based only on TBW is not optimal, whereas precision dosing of an ADC based on the inclusion of novel metrics of IIS biomarkers, body habitus, and sex may be more appropriate to reduce variability in PK exposure, reduce toxicity, and improve response.
Exploring Associations Between COVID-19 Bivalent Vaccines and Their Related Adverse Events: A Correlational Study
Tao, Wei , Sun, Zenan , Chen, Yong , Li, Yiming , Lundin, Sori Kim , Dang, Yifang , Tao, Cui

Mayo Clinic

No container title available | March 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6152825/v1 | PMID 40162215 Get It

Abstract Introduction COVID-19, a global health crisis, prompted rapid vaccine development. Bivalent vaccines by Pfizer-BioNTech and Moderna target both original and Omicron strains. Despite vaccination efforts, the persistence of adverse events underscores the importance of ongoing safety monitoring. Method We collected COVID-19 bivalent vaccine adverse event reports from the Vaccine Adverse Event Reporting System (VAERS) (September 15, 2022, to September 1, 2023). The Medical Dictionary for Regulatory Activities (MedDRA) categorized reported symptoms into corresponding concepts. Statistical analyses included zero-truncated Poisson regression for estimating symptom rates, logistic regression for identifying risk factors, and Spearman correlation for assessing non-parametric relationships between adverse events in different System Organ Classes (SOCs). Results Our analysis of COVID-19 bivalent vaccine adverse events identified significant correlations between SOCs. Notably, a positive correlation (ρ = 0.3) linked Infections (SOC 1) with Respiratory disorders (SOC 13), while a negative correlation (ρ=-0.3) connected Investigations (SOC 23) with Injury (SOC 24). Zero-truncated Poisson modeling estimated an average of 6.179 symptoms per individual, varying by age, gender, and vaccine. Gender and age significantly influence reported adverse events associated with COVID-19 bivalent vaccines. Females generally experienced higher odds for most SOCs compared to males, except for cardiac and product-related issues. Older adults showed a higher likelihood of symptoms across various SOCs, while children and adolescents had distinct susceptibility patterns. Additionally, Moderna and Pfizer vaccines were associated with different SOCs, with Moderna linked mainly to immune and skin disorders and Pfizer associated primarily with cardiac and metabolic issues. Conclusion In conclusion, our study aligned self-reported items with widely-accepted medical terminology and rigorously analyzed adverse events following COVID-19 bivalent vaccine using advanced statistical methods. The significant findings provide crucial insights, guiding evidence-based strategies and interventions for vaccine safety.